Allied Health Professionals Day
Nurses Stream Preliminary Programme
| 12:00 – 13:00 | REGISTRATION AND LUNCH |
| 13:00 – 15:00 | JOINT SESSION BLEEDING DISORDERS THROUGH LIFE | Paul McLaughlin |
| 13:00-13:10 | Opening message | Flora Peyvandi |
| 13:10-13:15 | Introduction | Paul Mclaughlin |
| 13:15-13:45 | Case study: a young patient with severe FIX deficiency and comorbidities | Mary Kavanagh |
| 13:45-14:15 | Case study presentation on menopause | Christina Burgess |
| 14:15-14:45 | Case study presentation on care home | Anne Juanos |
| 14:45-15:00 | Discussion and wrap-up | |
| 15:00 – 15:30 | Break | |
| 15:30 – 16:10 | NURSES SESSION 1 SLAM | Renester Fenton & Greta Mulders |
| 15.30-15.35 | Welcome | Nanda Uitslager (NL) |
| 15.35-15.41 | Differences in Practice in the Use of Desmopressin in Adults with Bleeding Disorders Throughout the Republic of Ireland and the United Kingdom | Roisin Ward (IE) |
| 15.41-15.47 | Nurse-led education for female haemophilia carriers throughout their lives | Nuria Caballero (ES) |
| 15.47-15.53 | Interim results from the lived experience of von Willebrand disease (VWD 360) study | Kate Khair (GB) |
| 15.53-15.59 | The intergenerational impact of the contaminated blood scandal | Sally-Anne Wherry (GB) |
| 16.00-16.10 | Q&A |
| 16.10 – 17.00 | NURSES SESSION 2 MASTERCLASS: GENETICS | Malin Axelsson |
| 16.10-16.30 | Explaining genetics C counselling | Nadine Andersson Gretenkort |
| 16.30-16.50 | Making a family tree | |
| 16.50-17.00 | Report back | |
| 17.00-17.35 | Break | |
| 17.30 – 18.45 | NURSES SESSION 3 HOW DO YOU MANAGE RARE BLEEDING DISORDERS | Linda Myrin Westesson |
| 17:30-17:40 | Case study on Afibrinogenemia | Nina Jurander |
| 17:40-17:50 | Case study on Severe Factor X Deficiency | Synne Hole Ane Halbrendt |
| 17:50-18:00 | Case study on Severe Factor V Deficiency | Niamh Larkin |
| 18:00-18:20 | Glanzmann: the 360 study | Kate Khair |
| 18:20-18:45 | Q&A | |
| 18.45 – 18.50 | WRAP UP AND CLOSING REMARKS | Nanda Uitslager |
| 18.50 – 19.00 | BEST SLAM PRESENTATION AND STAR EUROPEAN NURSE AWARD | Maj Friberg Birkedal |
| 19:00 – 21:00 | Networking reception *With short speeches by the EAHAD AHP Committees recapping the day | |
Physiotherapists Stream Preliminary Programme
| 12:00 – 13:00 | REGISTRATION AND LUNCH |
| 13:00 – 15:00 | JOINT SESSION BLEEDING DISORDERS THROUGH LIFE | Paul McLaughlin |
| 13:00-13:10 | Opening message | Flora Peyvandi |
| 13:10-13:15 | Introduction | Paul Mclaughlin |
| 13:15-13:45 | Case study: a young patient with severe FIX deficiency and comorbidities | Mary Kavanagh |
| 13:45-14:15 | Case study presentation on menopause | Christina Burgess |
| 14:15-14:45 | Case study presentation on care home | Anne Juanos |
| 14:45-15:00 | Discussion and wrap-up | |
| 15:00 – 15:30 | Break | |
| 15:30 – 16:10 | PHYSIOTHERAPISTS SESSION 1 SLAM | Paula Loughnane & Magnus Aspdahl |
| 15.30-15.35 | Welcome | |
| 15.35-15.41 | Psychometric Evaluation of the Timed Up and Go (TUG) Test in Adults with Haemophilia | Fabian Tomschi (DE) |
| 15.41-15.47 | Thermographic change and muscle strength examination in children with haemophilia who had at least one time history of bleeding at lower extremity | Hande Guney Deniz (TR) |
| 15.47-15.53 | Understanding healthcare professionals experiences and perceived competencies for pain management in people with haemophilia – a qualitative study | Paul McLaughlin (GB) |
| 15.53-15.59 | Measurement properties of a core outcome set monitoring physical capability in people with haemophilia | David Stephensen (GB) |
| 16.00-16.10 | Q&A | |
| 16.10 – 17.00 | PHYSIOTHERAPISTS SESSION 2 DEBATE: AGEING IN HAEMOPHILIA: IS JOINT SCREENING FUTILE? | Paul McLaughlin Merel Timmer |
| 16.10-16.20 | Ageing in haemophilia: State of the art | William McKeown |
| 16.20-16.50 | Joint screening is futile | Sofia Pérez-Alenda (in favour)/ Victor Jimenez-Yuste (against) |
| 16.50-17.00 | Q&A | |
| 17.00-17.35 | Break | |
| 17.30 – 18.45 | PHYSIOTHERAPISTS SESSION 3 CONSIDERING COMORBIDITIES IN PEOPLE WITH BLEEDING DISORDERS | Marie Katzerova Nathalie Grinda | ||
| 17:30-17:48 | Cardiometabolic issues | Megan Kennedy | ||
| 17:48-18:06 | Bone health issues | Laurent Frenzel | ||
| 18:06-18:24 | Setting up a haemophilia-specific pain management service | Aine O’Gara | ||
| 18:24-18:42 | Orthopaedic surgery in people with haemophilia | Luigi Piero Solimeno | ||
| 18.42 – 19.00 | WRAP-UP AND CLOSING REMARKS | |||
| 19:00-21:00 | Networking reception *With short speeches by the EAHAD AHP Committees recapping the day | |||
Psychosocial Professionals Preliminary Programme*
| 12:00 – 13:00 | REGISTRATION AND LUNCH |
| 13:00 – 15:00 | JOINT SESSION BLEEDING DISORDERS THROUGH LIFE | Paul McLaughlin |
| 13:00-13:10 | Opening message | Flora Peyvandi |
| 13:10-13:15 | Introduction | Paul Mclaughlin |
| 13:15-13:45 | Case study: a young patient with severe FIX deficiency and comorbidities | Mary Kavanagh |
| 13:45-14:15 | Case study presentation on menopause | Christina Burgess |
| 14:15-14:45 | Case study presentation on care home | Anne Juanos |
| 14:45-15:00 | Discussion and wrap-up | |
| 15:00 – 15:30 | Break | |
| 15:30 – 17:05 | PSYCHOSOCIAL PROFESSIONALS SESSION 1 WORKSHOP ON ETHICAL ISSUES | Christina Burgess Gaby Golan |
| 15:30-15:35 | Welcome | Christina Burgess |
| 15:35-15:50 | Introduction | Gaby Golan |
| 15:50-16:05 | Point of view of medical psychology | Alice van Dijk-Lokkart |
| 16:05-16:20 | Scenario 1: Novel Therapies and Gene Therapy | Ilaria Cutica Gaby Golan |
| 16:20-16:32 | Small group discussion | |
| 16:32-16:35 | Feedback | |
| 16:35-16:50 | Scenario 2: Confidentiality | Christina Burgess Gaby Golan |
| 16:50-17:02 | Small group discussion | |
| 17:02-17:05 | Feedback | |
| 17:05-17.10 | Take away message | Christina Burgess Gaby Golan |
| 17.10-17.30 | Break | |
| 17.30 – 18.45 | PSYCHOSOCIAL PROFESSIONALS SESSION 2 TRAUMATIC EXPERIENCES IN HAEMOPHILIA | Lotte Haverman Karolien Bartels |
| 17:30-17:35 | Introduction | Karolien Bartels |
| 17:35-17:55 | Psychosocial barriers in haemophilia | Grainne O’Brien and Gloria Rooney |
| 17:55-18:15 | Trauma and pain memories in IBD | Anna Wells |
| 18:15-18:45 | Case study – EMDR Treatment | Alice van Dijk-Lokkart and Petra Buckova |
| 18.45 – 19.00 | CLOSING REMARKS AND FUTURE DIRECTION | |
| 19:00 – 21:00 | Networking reception *With short speeches by the EAHAD AHP Committees recapping the day | |
*The stream is dedicated to the memory of Ana Torres Ortuño, a beloved and dedicated member of the EAHAD Psychosocial Professionals Committee, who passed away in September 2024.
| 09.00 – 11.00 | MULTIDISCIPLINARY EDUCATIONAL SESSION Workshop on Ultrasound: Joint Health in Haemophilia – where are we going | Jan Blatny |
| 09:00 – 09:10 | Allied Health Professionals Day Recap | Nanda Uitslager Ruth Elise Dybvik Matlary Christina Burgess |
| 09:10-10:50 | Panel discussion | Jan Blatny Roberta Gualtierotti Merel Timmer Carlo Martinoli Maj Friberg Birkedal Roberto Carioli |
| 10.50 – 11.00 | Q&A and Closing Thoughts | |
| 11.00 – 11.30 | Coffee Break/Poster Viewing | |
| 11.30 – 18.30 | SATELLITE SYMPOSIA | |
| 11.30 – 12.45 | Satellite Symposium 1 | |
| Satellite Symposium 2 | ||
| Satellite Symposium 3 | ||
| 12.45 – 13.45 | Lunch Break | |
| 13.45 – 15.00 | Satellite Symposium 4 | |
| Satellite Symposium 5 | ||
| Satellite Symposium 6 | ||
| 15.00 – 15.30 | Coffee Break | |
| 15.30 – 16.45 | Satellite Symposium 4 | |
| Satellite Symposium 8 | ||
| Satellite Symposium 9 | ||
| 16.45 – 17.15 | Coffee Break | |
| 17.15 – 18.30 | Satellite Symposium 10 | |
| Satellite Symposium 11 | ||
| 18:30 – 19:30 | Welcome Reception and Poster Presentations | |
| 08.30 – 09.00 | WELCOME AND INTRODUCTION | Flora Peyvandi |
| 09.00 – 10.30 | SESSION 1 Modern era of diagnosis and treatment | Flora Peyvandi Jan Blatny |
| 09.00 – 09.30 | Coagulation revisited: novel concepts to know in hemostasis | Wolfram Ruf |
| 09.30 – 10.00 | The role of next generation sequencing in bleeding disorders | Rosanna Asselta |
| 10.00 – 10.30 | How AI can improve early diagnosis in bleeding disorders | Sergio Mascetti |
| 10.30 – 11.00 | Coffee Break/Poster Viewing | |
| 11.00 – 12.30 | SESSION 2 A century of von Willebrand Disease | Ana Boban Raimondo de Cristofaro |
| 11.00 – 11.30 | VWD diagnosis and optimal treatment | Carlo Castaman |
| 11.30 – 12.00 | Demographics and epidemiology of VWD using big data | Omid Seidizadeh |
| 12.00 – 12.30 | Novel therapies in VWD | Frank Leebeek |
| 12.30 – 13.30 | Lunch Break/Poster Viewing/EAHAD Annual General Meeting | |
| 13.30 – 14.30 | SESSION 3 Current and Rapid Developments Around Novel Therapies EAHAD-ISTH Joint Session | Jan Blatný (EAHAD) Pantep Angchaisuksiri (ISTH) |
| 13.30 – 14.00 | Opportunities and Challenges of Novel Therapies | Peter Lenting |
| 14.00 – 14.30 | Monitoring haemophilia treatment | Armando Tripodi |
| 14.30 – 15.00 | Coffee Break/Poster Viewing | |
| 15.00 – 16.30 | SESSION 4 Gene Therapy | Wolfgang Miesbach Pratima Chowdary |
| 15.00 – 15.20 | Gene Therapy in haemophilia and emerging technologies | David Lillicrap |
| 15.20 – 15.40 | Experience of European centres treating patients with commercially available Gene Therapy | Robert Klamroth Flora Peyvandi |
| 15.40 – 15.55 | Coagulation Factor measurements during GT in haemophilia | Anne Riddell |
| 15.55 – 16.10 | The Role of the haemophilia treatment centre nurse in Gene Therapy | Greta Mulders |
| 16.10 – 16.30 | Discussion | |
| 16.30 – 16.45 | Coffee Break/Poster Viewing | |
| 16.45 – 17.25 | SESSION 5 EAHAD Research Grant Reports | Jan Blatny Robert Klamroth | |
| 16.45 – 16.55 | Neutrophils wandering in patients with haemophilia (New path) | Heike Hawerkamp | |
| 16.55 – 17.05 | Analysis of FVIII reservoirs on cell surfaces and their potential impact on coagulation | Chistoph Königs | |
| 17.05 – 17.15 | Sexual functioning in men with haemophilia: measurement and communication | Lotte Haverman | |
| 17.15 – 17.25 | Examination of the acceptability of digitalisation of the Timed Up and Go test for remote assessment in people with haemophilia | Louise Crossley | |
| 17.25 – 17.55 | EAHAD Lifetime Achievement Awards 2025 and EAHAD honorary membership induction | Jan Blatny Flora Peyvandi Robert Klamroth | |
| 17.25 – 17.35 | Monica Gobbi (EAHAD Lifetime Achievement award) | ||
| 17.35 – 17.45 | David Lillicrap (EAHAD Lifetime Achievement award ) | ||
| 17.45 – 17.55 | Mike Makris (EAHAD Honorary Membership) | ||
| 17.55 – 18.05 | Poster awards and 2024 research grants awards | Ana Boban | |
| 20.00 – 00:00 | Networking Evening |
| 08.30 – 10.00 | SESSION 6 SLAM | Samantha Gouw Ana Boban |
| 08:30 – 08:39 | OR 01 – FRONTIER3: Safety and efficacy of Mim8 prophylaxis in paediatric patients with haemophilia A | Johnny Mahlangu |
| 08:39 – 08:48 | OR 02 – Efanesoctocog Alfa for the Perioperative Management of Patients with Severe Haemophilia A: 4 years of Experience in the XTEND Clinical Program | Anthony K.C Chan |
| 08:48 – 08:57 | OR 03 – Pharmacodynamics (PD) and pharmacokinetics (PK) of dirloctocogene samoparvovec in people with severe to moderately severe hemophilia A (HA) | Lindsey George |
| 08:57 – 09:06 | OR 04 – Immune tolerance induction (ITI) in haemophilia A inhibitor patients: MOTIVATE first per protocol interim analysis | Carmen Escuriola Ettingshausen |
| 09:06 – 09:15 | OR 05 – Elevating Levels of Endogenous Circulating von Willebrand Factor (VWF): The Potential of HMB-002 as a Prophylactic Treatment of von Willebrand Disease (VWD) | Henrik Ostergaard |
| 09:15 – 09:24 | OR 06 – Screening and surveillance pathway for patients with Hermansky–Pudlak syndrome at risk of pulmonary fibrosis | Janine Collins |
| 09:24 – 09:33 | OR 07 – Factor VIII Activity Elevations Above Normal Ranges Post Giroctocogene Fitelparvovec: Characterization and Clinical Management in the Phase 3 AFFINE Trial | Laurent Frenzel |
| 09:33 – 09:42 | OR 08 – Activated Prothrombin Complex Concentrate in Patients Receiving Non-Factor Therapies: From Evidence to Clinical Practice | Robert F. Sidonino Jr |
| 09:42 – 09:51 | OR 09 – Outcomes by Dose Escalation Criteria in Participants With Hemophilia A or B Without Inhibitors Receiving Marstacimab in the BASIS Trial | Laurent Frenzel |
| 09:51 – 10:00 | OR 10 – Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B | Natalie Pursell |
| 10.00 – 10.30 | Coffee Break/Poster Viewing | |
| 10.30 – 11:30 | SESSION 7 EAHAD Activities | Niamh O’Connell Maria Teresa Alvarez Roman |
| 10.30 – 10.45 | EUHASS | Samantha Gouw |
| 10.45 – 11.00 | Glanzmann Thrombasthenia Working Group update | Roger Schutgens |
| 11.00 – 11.15 | Psychosocial principles of care in the age of GT | Lotte Haverman |
| 11.15 – 11.30 | WGBD+ update | Karin van Galen |
| 11:30 – 12:00 | AROSENIUS LECTURE 2025 | Fariba Baghaei |
| EAHAD – Paths to Progress | Christopher Ludlam | |
| 12:00 – 12:45 | Lunch Break | |
| 12.45 – 13.45 | SESSION 8 Aging population with rare bleeding disorders | Fariba Baghaei Pier Mannuccio Mannucci |
| 12.45 – 13.05 | Frailty in Haemophilia | William McKeown |
| 13.05 – 13.25 | Management of thrombosis in elderly patients with haemophilia | Cihan Ay |
| 13.25 – 13.45 | Psychosocial aspects of coping with aging in haemophilia | Christina Burgess |
| 13.45 – 15.15 | SESSION 9 Latest Clinical Trial Results Session | Jan Blatny & Flora Peyvandi |
| 13:45 – 14:00 | OR 11 – Thrombotic rates in bleeding disorder individuals treated with concentrate or bispecific antibody. Fifteen year EUHASS data with 209,058 patient year exposure | Mike Makris |
| 14:00 – 14:15 | OR 12 – Two-Year Clinical Outcomes of Once-Weekly Efanesoctocog Alfa Prophylaxis in Children with Severe Hemophilia A: Second Interim Analysis of the XTEND-ed Phase 3 Study | Lynn Malec |
| 14:15 – 14:30 | OR 13 – Long-Term Efficacy of Marstacimab in Adults and Adolescents With Severe Hemophilia A or B Without Inhibitors Who Completed the BASIS Trial | Davide Matino |
| 14:30 – 14:45 | OR 14 – The phase 3 HOPE-B trial shows 4-year durability of sustained near-normal FIX activity, bleed protection and favourable safety in adults with severe or moderately severe haemophilia B | Steven Pipe |
| 14:45 – 15:00 | OR 15 – Safety and Efficacy of HMB-001 as a Prophylactic Treatment of Glanzmann Thrombasthenia: Interim Analysis of Phase 1/2 Study | Suthesh Sivapalaratnam |
| 15:00 – 15:15 | OR 16 – Phase I Study of VGA039, a Protein S-targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Sustained Drug Concentrations, Increased Thrombin Generation, and Decreased Bleeding Following a Single Subcutaneous Injection | Carolyn M. Millar |
| 15.15 – 15.45 | Closing remarks and Save the Date for EAHAD 2026 | Flora Peyvandi & Niamh O’Connell |